Other substances

(S)-3-((S)-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido) propanamido)-2-oxo-N,4-diphenylbutanamide

An α-ketoamide derivative.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
25
 Clinical trials

General information

(S)-3-((S)-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido) propanamido)-2-oxo-N,4-diphenylbutanamide is an α-ketoamide derivatives with anti-SARS-CoV-2 activity in vitro (Wang et al., 2021).

(Structure image generated in SwissSimilarity)

Synonyms

17

 

Structure image - (S)-3-((S)-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido) propanamido)-2-oxo-N,4-diphenylbutanamide

COC1=CC=C(C[C@@H](NC(=O)[C@@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)C(=O)NC2=CC=CC=C2)C=C1

Supporting references

Link Tested on Impact factor Notes Publication date
A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities
Small molecule In vitro In silico 		in silico; Vero E6 cells; Caco-2 cells (cytotoxicity only); SARS-CoV-2 live virus 5.57

Inhibited SARS-CoV-2 infection in Vero E6 cells with an EC50 of 1.28 μM with relatively low cytotoxicity (also in Caco-2 cells). It was predicted to bind m-calpain.

 Feb/10/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT05007080 A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive Recruiting Phase 2|Phase 3 Sep/27/2021 Dec/03/2024
  • Alternative id - CR108966|2020-005720-11|VAC31518COV3006
  • Interventions - Biological: Ad26.COV2.S
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CIPREC, Buenos Aires, Argentina|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Buenos Aires, Argentina|CEMEDIC, Buenos Aires, Argentina|Hospital Pedro de Elizalde, City of Buenos Aires, Argentina|Clinical Trials Division-Stamboulian Servicios de Salud, Ciudad Autonoma Buenos Aires, Argentina|Centro Medico Barrio Parque. Swiss Medical Group, Ciudad Autonoma de Buenos Aires, Argentina|Fundacion Huesped, Ciudad Autonoma De Buenos Aire, Argentina|Hospital de Ninos de Cordoba, Córdoba, Argentina|Instituto Medico Platense, La Plata, Argentina|Centro de Investigaciones Medicas Mar Del Plata, Mar del Plata, Argentina|DIM Clinica Privada, Ramos Mejia, Argentina|Instituto Médico Río Cuarto, Río Cuarto, Argentina|Hospital del Niño Jesús, San Miguel de Tucumán, Argentina|Hospital de Clinicas da Universidade Federal De Minas Geraisnas Gerais, Belo Horizonte, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil|L2IP - Instituto de Pesquisas Clínicas, Brasília, Brazil|HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, Campinas, Brazil|Núcleo de Medicina Tropical - Universidade Federal do Ceará, Ceará, Brazil|Hospital São José, Criciúma, Brazil|Hospital Pequeno Principe, Curitiba, Brazil|Centro Medico Sao Francisco, Curitiba, Brazil|Fundação De Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil|Centro de Estudos e Pesquisas em Moléstias Infecciosas, Natal, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Hospital das Clinicas FMRP-USP, Ribeirão Preto, Brazil|Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ, Rio de Janeiro, Brazil|Hospital Geral de Nova Iguacu - HGNI DST/AIDS, Rio De Janeiro, Brazil|Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto, Sao Jose do Rio Preto, Brazil|CMPC - Consultoria Médica e Pesquisa Clínica, Sorocaba, Brazil|CPQuali Pesquisa Clinica LTDA ME, São Paulo, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo, São Paulo, Brazil|Clinica de la Costa, Barranquilla, Colombia|Medplus Medicina Prepagada S.A., Bogota, Colombia|Centro de Investigaciones Clinicas S.A.S., Cali, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Chia, Colombia|Hospital Pablo Tobon Uribe, Medellín, Colombia|Corporación Clínica Universidad Cooperativa De Colombia Clínica Ucc, Villavicencio, Colombia|Sri ramchandra Medical College & Research Institute, Chennai, India|Sir Ganga Ram Hospital, Delhi, India|Medanta The Medicity, Gurugram, India|G.S.V.M. Medical College, Kanpur, India|Peerless Hospitex Hospital And Research Center Ltd., Kolkata, India|Cheluvamba Hospital, Mysore, India|JSS Hospital, Mysore, India|Supe Heart And Diabetes Hospital and Research Center, Nashik, India|D.Y.Patil Medical College, Pune, India|KEM Hospital & Research Centre, Pune, India|BAPS Pramukhswami Hospital, Surat, India|Acharya vinoba bhave rural hospital, Wardha, India|Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico|Instituto Nacional de Pediatría, Ciudad de Mexico, Mexico|CAIMED Investigacion en salud S.A de C.V., Ciudad de Mexico, Mexico|Hospital Infantil de Mexico Federico Gomez, Ciudad De Mexico, Mexico|Hospital General Dr. Manuel Gea González, Ciudad de México, Mexico|Instituto Nacional de Salud Publica, Cuernavaca, Mexico|Unidad Medicina Familiar 52 IMSS, Estado de México, Mexico|Köhler & Milstein Research SA de CV, Merida, Mexico|Hospital Universitario 'Dr. Jose Eleuterio Gonzalez', Monterrey, Mexico|Norzel MedicaL and Diagnostic Clinic, Cebu City, Philippines|De La Salle Health Sciences Institute- DLSUMC, Dasmarinas, Philippines|Healthlink Medical, Surgical, Dental Clinic and Diagnostic Center, Iloilo City, Philippines|West Visayas State University Medical Center, Iloilo City, Philippines|Philippine General Hospital, Manila, Philippines|Family Clinical Research Unit FAM-CRU, Cape Town, South Africa|Ndlovu Elandsdoorn Site, Dennilton, South Africa|Perinatal HIV Research Unit, Guateng Province, South Africa|Shandukani Research Centre, Johannesburg, South Africa|PHOENIX PHARMA (Pty) Ltd, Port Elizabeth, South Africa|Setshaba Research Centre, Soshanguve, South Africa|Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa|University of Witwatersrand - Helen Joseph Hospital - Themba Lethu Hiv Research Centre, Westdene Johannesburg Gauteng, South Africa|Siriraj hospital - Faculty of Medicine,Mahidol University - Department of Pediatrics, Bangkok, Thailand|Research Institute for Health Sciences, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|Faculty of Medicine, Thammasat University, Pathumthani, Thailand|Faculty of Medicine Chulalongkorn University, Pathumwan, Thailand
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 3300
  • Age - 12 Years to 17 Years   (Child)
  • Outcome measures - Parts 1 and 2: Number of Participants with Solicited Local Adverse Events (AEs) 7 Days Post-dose 1|Parts 1 and 2: Number of Participants with Solicited Local Adverse Events (AEs) 7 Days Post-dose 2|Parts 1 and 2: Number of Participants with Solicited Systemic AEs 7 Days Post-dose 1|Parts 1 and 2: Number of Participants with Solicited Systemic AEs 7 Days Post-dose 2|Parts 1 and 2: Number of Participants with Unsolicited AEs 28 Days Post-dose 1|Parts 1 and 2: Number of Participants with Unsolicited AEs 28 Days Post-dose 2|Parts 1 and 2: Number of Participants with Medically-attended Adverse Events (MAAEs)|Parts 1 and 2: Number of Participants with MAAEs|Parts 1 and 2: Number of Participants with MAAEs Leading to Discontinuation|Parts 1 and 2: Number of Participants with Serious Adverse Events (SAEs)|Parts 1 and 2: Number of Participants with Adverse Events of Special Interest (AESI) (Including Multisystem Inflammatory Syndrome in Children [MIS-C])|Part 1: Serological Response to Vaccination Measured by Enzyme-linked Immunosorbent Assay (S-ELISA) or Equivalent Assay 28 Days Post-dose 1|Part 1: Serological Response to Vaccination Measured by S-ELISA or Equivalent Assay 14 Days Post-dose 2|Parts 1 and 2: Serological Response to Vaccination Measured by Virus Neutralization Assay (VNA) Titers 28 Days Post-dose 1|Parts 1 and 2: Serological Response to Vaccination Measured by VNA Titers 14 Days Post-dose 2|Part 2: Seroresponse Rate of VNA to 28 Days Post-dose 1|Part 2: Seroresponse Rate of VNA to 14 Days Post-dose 2|Part 2: Humoral Immune Response Expressed by the Geometric Mean Titer (GMT) of VNA 28 Days Post-dose 1 in Adolescents|Part 2: Humoral Immune Response Expressed by the Seroresponse Rate of the VNA 28 Days after First Vaccination in Adolescents|Part 2: Humoral Immune Response Expressed by the GMT of VNA 28 Days Post-dose 1 in Adolescents|Part 2: Serological Response to Vaccination as Measured by the GMT of VNA 14 Days Post-dose 2 in Adolescents|Part 2: Humoral Immune Response Expressed by the Seroresponse Rate of the VNA 14 Days Post-dose 2 in Adolescents|Part 2: Humoral Immune Response Expressed by the GMT of VNA 14 Days Post-dose 2 in Adolescents|Parts 1 and 2: Severe Acute Respiratory Syndrome Coronavirus(-2) (SARS-CoV-2) or Individual SARS-CoV-2 Protein Binding Antibody Titers as Measured by S-ELISA (or Equivalent Assay)|Parts 1 and 2: SARS-CoV-2 Neutralizing Antibody Titers as Measured by VNA Titers
NCT04927182 Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19. Completed Not Applicable Oct/15/2020 Sep/30/2021
  • Alternative id - REC/00877 Nayab Saleem
  • Interventions - Other: Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)|Other: Moderate Exercise Training (Age Group 2; 31 to 45 years)|Other: Moderate Exercise Training (Age Group 3; Above 45 years)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - General Population, Rawalpindi, Punjab, Pakistan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  • Enrollment - 102
  • Age - 17 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Modified Borg Scale of Perceived Exertion|Systolic and diastolic blood pressure|Nordic Musculoskeletal questionnaire|6 Min walk test (Distance in meters)|Peak VO2 with formula|Heart Rate/Pulse Rate
NCT04917523 Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above Not yet recruiting Phase 3 Jun/06/2021 Feb/06/2022
  • Alternative id - CNBG2021001
  • Interventions - Biological: SARS-CoV-2 Vaccine (Vero Cell), Inactivated
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 1800
  • Age - 3 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody|The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody|Safety index-Incidence of adverse reactions|Safety index-Incidence of serious adverse events|The distribution of neutralizing antibody titer
NCT05169008 A Study to Evaluate the Safety and Immunogenicity of a 2-dose Regimen COVID-19 Vaccine in Children and Adolescents Aged 6-17 Years Not yet recruiting Phase 3 Feb/20/2022 Aug/20/2023
  • Alternative id - CS-CTP-AD5NCOV-PDⅢ
  • Interventions - Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 2000
  • Age - 6 Years to 17 Years   (Child)
  • Outcome measures - Incidence of SAE|Immunogenicity of S-RBD IgG antibody|Incidence of Adverse Reactions (ARs)|The incidence of AR and AE|Immunogenicity of neutralizing antibodies|Baseline level of pre-existing anti Ad5 antibody
NCT05244330 Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2) Completed Dec/15/2021 Jan/15/2022
  • Alternative id - XJTU1AF2022LSK-001
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - First Affiliated Hospital of Xian JiaotongUniversity, Xi'an, Shaanxi, China
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 1500
  • Age - Child, Adult, Older Adult
  • Outcome measures - the proportion of severe and critical cases|the duration of viral shedding
NCT04982328 COVID-19 and Nonalcoholic Fatty Liver Disease Recruiting Apr/01/2021 Feb/15/2022
  • Alternative id - UHID07
  • Interventions - Diagnostic Test: Th17 cytokine profile|Diagnostic Test: Screening for the components of metabolic syndrome|Diagnostic Test: Evaluation of the degree of steatosis
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University Hospital for Infectious Diseases Zagreb, Zagreb, Croatia
  • Study designs - Observational Model: Case-Control|Time Perspective: Prospective
  • Enrollment - 120
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Th17 cytokines concentrations|Staging of liver steatosis|Duration of hospitalization|Remission of respiratory symptoms|28 days survival|Rate of high flow oxygen therapy or non-invasive ventilation|Secondary infections|Rate of invasive mechanical ventilation|Rate of pulmonary thromboembolism
NCT04961359 Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old) Recruiting Phase 1 Jul/03/2021 Dec/01/2022
  • Alternative id - LKM-2021-NCV01
  • Interventions - Biological: Recombinant new coronavirus vaccine (CHO cell) group|Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 75
  • Age - 3 Years to 17 Years   (Child)
  • Outcome measures - The number of adverse events after intramuscular injection|Immunogenic end point
NCT04544033 IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients Recruiting Sep/15/2020 May/01/2021
  • Alternative id - IL6 in egyptian COVID patients
  • Interventions - Diagnostic Test: interleuken 6 level measurment|Diagnostic Test: Interleukin-6 Gene-174C detection
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Bsant Safwat Kasem, Tanta, El Gharbyia, Egypt
  • Study designs - Observational Model: Case-Only|Time Perspective: Prospective
  • Enrollment - 120
  • Age - Child, Adult, Older Adult
  • Outcome measures - interleuken- 6 gene (174G/C) single nucleotide polymorphism|interleukin 6 level
NCT04705597 Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure Recruiting Phase 2 Mar/18/2021 Sep/01/2022
  • Alternative id - BGE-175-201
  • Interventions - Drug: BGE-175|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Banner Health, Mesa, Arizona, United States|Velocity Clinical Research, Chula Vista, Chula Vista, California, United States|Long Beach Medical Center, Long Beach, California, United States|UCI Center for Clinical Research, Orange, California, United States|Sharp Memorial Hospital, San Diego, California, United States|North Colorado Medical Center, Greeley, Colorado, United States|Stamford Hospital, Stamford, Connecticut, United States|University of Florida - Health, Jacksonville, Jacksonville, Florida, United States|Baptist Health, Lexington, Lexington, Kentucky, United States|University of Maryland Medical System, Baltimore, Maryland, United States|Clinica Privada Independencia, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Sanatorio De La Trinidad Mitre, Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina|Clinica Adventista Belgrano (CAB), Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina|Hospital Universitário Cassiano Antônio de Moraes, Vitória, Espiritu Santo, Brazil|Hospital Felicio Rocho (HFR), Belo Horizonte, Minas Gerais, Brazil|Centro de Pesquisa Hospital Ana Nery Santa Cruz do Sul, Santa Cruz Do Sul, Rio Grande Do Sol, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Rio Grande Do Sul, Brazil|Clínica Supera Oncologia, Chapecó, Santa Catarina, Brazil|Unidade de Pesquisa Clinica da Fundação Pio XII - Hospital de Amor de Barretos, Barretos, Sao Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina de Botucatu UNESP (HC-FMB/UNESP), Botucatu, Sao Paulo, Brazil|Pontificia Universidade Catolica de Campinas (PUC-CAMP) - Hospital e Maternidade Celso Pierro (HMCP) - Centro de Pesquisa São Lucas, Campinas, Sao Paulo, Brazil|Clinica de Alergia Martti Antila, Sorocaba, Sao Paulo, Brazil|Conjunto Hospitalar de Mandaqui, São Paulo, Sao Paulo, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil|Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz (FIOCRUZ), Rio De Janeiro, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 312
  • Age - 50 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of participants who have died or progressed to respiratory failure|Proportion of participants experiencing treatment-emergent adverse events|Survival|Proportion of subjects who survive without progression to respiratory failure|Viral load|Clinical worsening on a 9-point ordinal scale|Clinical improvement|Time to extubation|Time to discharge from hospital intensive care unit|Incidence of supplemental oxygen administration|Duration of supplemental oxygen administration|Duration of noninvasive ventilation by nonrebreather mask or high-flow nasal cannula|Incidence of noninvasive ventilation by nonrebreather mask or high-flow nasal cannula|Duration of mechanical ventilation plus additional organ support using vasopressors, and/or renal replacement therapy and/or ECMO|Incidence of mechanical ventilation plus additional organ support using vasopressors, and/or renal replacement therapy and/or ECMO|Daily ratio of oxygen saturation (SpO2) to fractional inspired O2 (SpO2/FiO2)|Time to discharge from the hospital|Time to re-hospitalization|Proportion of participants requiring intensive care unit admission
NCT04927065 A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants Recruiting Phase 2|Phase 3 May/28/2021 Mar/31/2023
  • Alternative id - mRNA-1273-P205
  • Interventions - Biological: mRNA-1273.211|Biological: mRNA-1273|Biological: mRNA-1273.617.2|Biological: mRNA-1273.213|Biological: mRNA-1273.529
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Benchmark Research (California), Sacramento, California, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center For Clinical Research, Jacksonville, Florida, United States|Meridian Clinical Research-(Savannah Georgia), Savannah, Georgia, United States|Meridian Clinical Research (Iowa), Sioux City, Iowa, United States|Johnson County Clinical Trials, Lenexa, Kansas, United States|Meridian Clinical Research-(Baton Rouge, Louisiana), Baton Rouge, Louisiana, United States|Benchmark Research, Metairie, Louisiana, United States|Meridian Clinical Research-(Rockville Maryland), Rockville, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington State University, Saint Louis, Missouri, United States|Sundance Clinical Research, Saint Louis, Missouri, United States|Meridian Clinical Research (Grand Island, Nebraska), Grand Island, Nebraska, United States|Meridian Clinical Research (Norfolk-Nebraska), Norfolk, Nebraska, United States|Meridian Clinical Research-(Omaha Nebraska), Omaha, Nebraska, United States|Meridian Clinical Research, LLC, New York, New York, United States|Trial Management Associates, Wilmington, North Carolina, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Benchmark Research - Austin - HyperCore, Austin, Texas, United States|Tekton Research, Inc., Austin, Texas, United States|Benchmark Research - Fort Worth - HyperCore, Fort Worth, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|DM Clinical Research, Tomball, Texas, United States
  • Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 4720
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody|Seroresponse Rate of Vaccine Recipients|Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)|Number of Participants with Unsolicited Adverse Events (AEs)|Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs)|GMT of SARS-CoV-2-Specific Antibody
NCT04403061 Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome Completed May/22/2020 Jan/10/2021
  • Alternative id - EC128/20
  • Interventions - Diagnostic Test: Cytokines measurement|Diagnostic Test: Cellular response|Diagnostic Test: TLRs activation measurement|Diagnostic Test: KIR phenotype evaluation
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Hospital Ramon y Cajal, Madrid, Spain
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 106
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Changes in cytokines associated with SARS CoV-2 infection|Evaluation of cellular response|TLRs activation|KIR phenotype determination
NCT05112913 Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years Active, not recruiting Phase 4 Jul/27/2021 Jun/25/2022
  • Alternative id - PRO-nCOV-MA4006-SN
  • Interventions - Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2|Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2|Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2|Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3|Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3|Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3|Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Yaliang county Center for Disease Control and Prevention, Xi'an, Shanxi, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 2520
  • Age - 3 Years to 17 Years   (Child)
  • Outcome measures - Geometric mean titer(GMT) of neutralizing antibody to live SARS-CoV-2|Geometric mean increase (GMI) of the neutralizing antibody to live SARS-CoV-2|Seroconversion rate of the neutralizing antibody to live SARS-CoV-2|Seropositivity rate of the neutralizing antibody to live SARS-CoV-2|Incidence of adverse reactions 0-7 days after vaccination|Incidence of adverse reactions 0-28 days after vaccination
NCT05194033 Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 1) Not yet recruiting Not Applicable Mar/01/2022 Mar/01/2023
  • Alternative id - GUANKE-Trial 1
  • Interventions - Dietary Supplement: Probiotics daily|Dietary Supplement: Placebo daily
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Beijing Pinggu Hospital, Beijing, China|Peking University Health Science Center Hospital, Beijing, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other
  • Enrollment - 30
  • Age - 18 Years to 59 Years   (Adult)
  • Outcome measures - The serum neutralizing antibody level of SARS-CoV-2.|IgG antibody concentration|T-cell response level|Serum neutralizing antibody positive rate|Serum neutralizing antibody positive conversion rate|Intestinal flora|Blood pressure|Blood glucose|Blood lipid
NCT05069610 Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild COVID-19 Recruiting Phase 1|Phase 2 Dec/15/2021 Apr/15/2022
  • Alternative id - AD17002-SC01
  • Interventions - Biological: AD17002|Biological: Placebo (Formulation buffer)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Advagene Biopharma, Taipei, Taiwan|Chang Gun Medical Foundation, Taoyuan, Taiwan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 20 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - The proportion of participants who experience adverse events|The proportion of participants with treatment-emergent adverse events (TEAE) leading to investigational medicinal products (IMPs) discontinuation|Changes to the reverse transcription polymerase chain reaction (RT-PCR)|Proportion of participants who progress to SPO2≤93|The time to proportions of participants have a Ct≥28|Time to recovery* of fever (days)|Time to recovery* of sore throat (days)|Time to recovery* of cough (days|Time to recovery* of fatigue (days).|Time to recovery* of muscle/body pain (days)|Time to recovery* of other symptoms (days)|The mean change from baseline to each specified time point on National Early Warning Score 2 (NEWS2)
NCT05201625 Markers of Severity (CD177,S100A8 &S100A12) in Sever Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) Patients Recruiting Not Applicable Dec/15/2021 Dec/01/2022
  • Alternative id - Soh-Med-21-11-22
  • Interventions - Diagnostic Test: real time PCR
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Sohag University Hospital, Sohag, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  • Enrollment - 90
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Markers of severity(CD177) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients|Markers of severity(S100A8&S100A12) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients
NCT04549922 Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19 Active, not recruiting Phase 2 Oct/22/2020 Feb/01/2022
  • Alternative id - ASKCOV_Trial
  • Interventions - Drug: ISIS 721744|Drug: Normal Saline
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Naval Marcílio Dias, Rio De Janeiro, Brazil|BP-A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil|Hospital São Paulo - UNIFESP, São Paulo, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 111
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Days alive without respiratory support (any supplemental oxygen) after 15 days (DAFOR15)|SOFA - Sequential Organ Failure Assessment Score up to 15 days after randomization|Need for mechanical ventilation|Duration of mechanical ventilation
NCT05004181 Safety and Immunogenicity of a SARS CoV 2 Multivalent RNA Vaccine in Healthy Participants Recruiting Phase 2 Aug/25/2021 Aug/01/2023
  • Alternative id - BNT162-17|2021-003458-22
  • Interventions - Biological: BNT162b2|Biological: BNT162b2 (B.1.1.7 + B.1.617.2)|Biological: BNT162b2 (B.1.1.7)|Biological: BNT162b2 (B.1.617.2)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Collaborative Neuroscience Network LLC, Long Beach, California, United States|California Research Foundation, San Diego, California, United States|Clinical Research Consulting, Llc, Milford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Meridian Clinical Research, Savannah, Georgia, United States|Medpharmics, LLC, Gulfport, Mississippi, United States|Amici Clinical Research, Raritan, New Jersey, United States|Rochester Clinical Research, Rochester, New York, United States|Aventiv Research Inc., Columbus, Ohio, United States|ARC Clinical Research, Austin, Texas, United States|North Texas Infectious Diseases Consultants, Dallas, Texas, United States|Clinical Trials of Texas Inc., San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Virginia Research Center, Midlothian, Virginia, United States|CRS Clinical Research Services Berlin, Berlin, Germany|IKF Institut fuer klinische Forschung Frankfurt, Frankfurt am Main, Germany|CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany|Studienzentrum Brinkum Dr. Lars Pohlmeier und Torsten Drescher, Stuhr, Germany|JOSHA Research, Bloemfontein, Free State, South Africa|Synexus Helderberg Clinical Trial Centre, Pretoria, Gauteng, South Africa|Langeberg Medicross Medical Centre, Kraaifontein, Western Cape, South Africa|Paarl Research Centre, Paarl, Western Cape, South Africa|Worthwhile Clinical Trials, Benoni, South Africa|Tiervlei Trial Centre, Cape Town, South Africa|Midrand Medical Centre, Halfway House, South Africa|Newtown Clinical Research, Johannesburg, South Africa|Global Clinical Trials, Pretoria, South Africa|Botho ke Bontle Health Service, Pretoria, South Africa|Jongaie Research, Medicross Pretoria West, Pretoria, South Africa|Ankara University Faculty of Medicine, Avicenna Hospital, Ankara, Turkey|Hacettepe University Hospital, Ankara, Turkey|Bagcilar Medipol Mega University Hospital, Istanbul, Turkey|Istanbul University Medical Faculty, Istanbul, Turkey|Kocaeli Universitesi Tip Fakultesi, Kocaeli, Turkey
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 1245
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Percentage of participants reporting local reactions at the injection site|Percentage of participants reporting systemic events|Percentage of participants reporting adverse events (AEs)|Percentage of participants reporting serious adverse events (SAEs)|Part B - Geometric mean ratio (GMR) of B.1.1.7|Part B - GMR of B.1.617.2 NT 1 month after 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) on BNT162b2-experienced participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial|Part B - GMR of B.1.617.2 NT 1 month after 1 dose of BNT162b2 (B.1.617.2) on BNT162b2-experienced participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial|Part B - The difference in Seroresponse (SR) to B.1.1.7|Part B - The difference in SR to B.1.617.2|Part B - The difference in SR to B.1.617.2 NT 1 month after 1 dose of BNT162b2 (B.1.617.2) on BNT162b2-experienced participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial|Part B - GMR of B.1.1.7 NT 1 month after 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) on BNT162b2-naïve participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial|Part B - GMR of B.1.617.2 NT 1 month after 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) on BNT162b2-naïve participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial|Part B - The difference in SR to B.1.1.7 NT 1 month after 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) on BNT162b2-naïve participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial|Part B - The difference in SR to B.1.617.2 NT 1 month after 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) on BNT162b2-naïve participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial|Part A - Geometric mean titer (GMT)|Part A - Geometric mean fold rises (GMFR) from before vaccination to each subsequent time point after vaccination|Part A - SR in terms of NT at each post vaccination time point|Part B - GMT - B.1.1.7 + B.1.617.2 vs BNT162b2|Part B - GMT - B.1.617.2 vs BNT162b2|Part B - GMT - B.1.1.7 + B.1.617.2 to the reference strain
NCT04948515 Gene Polymorphism of IL17 and IL 23 Recruiting Jun/03/2021 Oct/03/2021
  • Alternative id - Soh-Med-21-04-35
  • Interventions - Diagnostic Test: laboratory test
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Sohag University, Sohag, Egypt
  • Study designs - Observational Model: Case-Control|Time Perspective: Cross-Sectional
  • Enrollment - 100
  • Age - Child, Adult, Older Adult
  • Outcome measures - genotyping of IL 17|genotyping of IL 23|estimation of serum level of IL 17
NCT05029856 Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults Not yet recruiting Phase 1|Phase 2 Feb/04/2022 Aug/01/2022
  • Alternative id - 2019nCoV-102
  • Interventions - Biological: SII B.1.351|Biological: SII Bivalent|Biological: SII B.1.617.2
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Australian Clinical Research Network (ACRN), Maroubra, New South Wales, Australia|Holdsworth House Medical Practice - Sydney, Sydney, New South Wales, Australia|University Hospital Geelong-Barwon Health, Geelong, Victoria, Australia|Emeritus Research, Melbourne, Victoria, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 240
  • Age - 18 Years to 64 Years   (Adult)
  • Outcome measures - MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as GMT|MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs|MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as GMT|MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as SCRs/SRRs|Incidence, duration, and severity of solicited local and systemic adverse events (AEs)|Incidence, duration, severity, and relationship of unsolicited AEs through 28 days|Incidence and relationship of medically attended adverse events (MAAEs), adverse events of special interest (AESIs) (predefined list), and serious adverse events (SAEs)|MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in previously vaccinated patients|MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in participants seronegative at baseline|MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in previously vaccinated patients|MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in participants seronegative at baseline.|MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in participants seronegative at baseline|MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in previously vaccinated participants|MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as SCRs/ SRRs in participants seronegative at baseline|MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as SCRs/ SRRs in previously vaccinated participants|IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in previously vaccinated participants|IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in participants seronegative at baseline|IgG geometric mean concentrations (GMCs) to the B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein in participants seronegative at baseline|IgG geometric mean concentrations (GMCs) to the B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein in previously vaccinated participants|Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in previously vaccinated participants|Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in participants seronegative at baseline|Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in previously vaccinated participants|Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in participants seronegative at baseline|Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in participants seronegative at baseline|Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in previously vaccinated participants|Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as SCRs/SRRs in participants seronegative at baseline|Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as SCRs/SRRs in previously vaccinated participants
NCT04809272 ePLH Pilot Study: Online Support Parent Groups - ParentChat Recruiting Not Applicable Mar/08/2021 Dec/01/2021
  • Alternative id - R72537/RE001
  • Interventions - Behavioral: ParentChat for parents of children ages 2-17
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Oxford, Oxford, Oxfordshire, United Kingdom
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 900
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Child maltreatment - physical abuse and emotional abuse: ISPCAN Child Abuse Screening Tool-Intervention (ICAST-TP) - Physical and Emotional Abuse Subscales|Child maltreatment - physical abuse and emotional abuse: Frequency of overall abuse|Positive parenting: Parent Daily Report Checklist|Parenting stress: Parent Daily Report Checklist|Child maltreatment - physical abuse and emotional abuse: Fortnightly Assessments|Positive parenting: Fortnightly Assessments|Parenting Stress: Fortnightly Assessments|Child behaviour problems: Child and Adolescent Behaviour Inventory (CAPI) - Parent Report|Child behaviour problems: Three Problem Rating Scale - Parent Report|Sexual abuse risk: Parent Report|Attitude toward punishment: Multiple Indicator Cluster Survey (MICS) 5 Child Discipline module - Parent Report|Parent well-being: Depression, Anxiety, and Stress Scale (DASS) - Parent Report|Parent exposure to IPV and intimate partner coercion: WHO Multi-Country Questionnaire on Women's Health and Domestic Violence against Women (WHO) - Parent Report|Parent exposure to IPV and intimate partner coercion: Revised Conflict Tactics Scale Short Form (CTS2S)
NCT04734886 The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19 Completed Not Applicable Nov/27/2020 Sep/13/2021
  • Alternative id - Provid
  • Interventions - Dietary Supplement: L. reuteri DSM 17938 + vitamin D|Dietary Supplement: Placebo + vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Örebro University, Örebro, Örebro Län, Sweden
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science
  • Enrollment - 161
  • Age - 18 Years to 60 Years   (Adult)
  • Outcome measures - SARS-CoV-2 specific antibodies|Maintenance of SARS-CoV-2 seroconversion in seropositive individuals|Duration of COVID-19 symptoms measured by a weekly symptom questionnaire|Severity of COVID-19 symptoms measured by Ordinal Scale for Clinical Improvement (scale 0-7, a lower score corresponds to a better outcome)|Secretory IgA (sIgA) antibodies|Blood group A antigen antibodies|Blood group B antigen antibodies|Tn antigen antibodies|Innate immune system activation|Cytokines|Total antibodies|T cell activation|B cell activation|Intestinal inflammation|Intestinal barrier function|Indirect marker of intestinal permeability
NCT05003466 Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19) Not yet recruiting Phase 2 Sep/01/2021 Apr/01/2023
  • Alternative id - 2020L001-2B
  • Interventions - Biological: SARS-CoV-2 Vaccine (Vero Cells), Inactivated|Biological: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hunan Provincial Center for Diseases Control and Prevention, Changsha, Hunan, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 480
  • Age - 3 Years to 17 Years   (Child)
  • Outcome measures - Seroconversion rate of SARS-CoV-2 neutralizing antibody|Geometric mean titer of SARS-CoV-2 neutralizing antibody|Incidence of adverse reactions/events|Serious Adverse Events (SAE)|Seroconversion rate of SARS-CoV-2 IgG binding antibody|Geometric mean titer of SARS-CoV-2 IgG binding antibody|Seropositive rate of SARS-CoV-2 neutralizing antibody|Seropositive rate of SARS-CoV-2 IgG binding antibody
NCT05003479 Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19) Not yet recruiting Phase 1 Aug/01/2021 Oct/01/2022
  • Alternative id - 2020L001-2A
  • Interventions - Biological: SARS-CoV-2 Vaccine (Vero Cells), Inactivated|Biological: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hunan Provincial Center for Diseases Control and Prevention, Changsha, Hunan, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 84
  • Age - 3 Years to 17 Years   (Child)
  • Outcome measures - Incidence of adverse reactions/events|Incidence of Serious Adverse Events (SAE)|Incidence of abnormal indicators of laboratory safety examinations(including blood routine, blood biochemistry, urine routine, thyroid function and coagulation function)|Geometric mean titer of SARS-CoV-2 neutralizing antibody|Geometric mean titer of SARS-CoV-2 IgG binding antibody|Seroconversion rate of SARS-CoV-2 neutralizing antibody|Seroconversion rate of SARS-CoV-2 IgG binding antibody|Seropositive rate of SARS-CoV-2 neutralizing antibody|Seropositive rate of SARS-CoV-2 IgG binding antibody
NCT05185804 Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19 Completed Phase 3 Feb/08/2021 Oct/29/2021
  • Alternative id - АМ217-03
  • Interventions - Drug: Dimolegin|Drug: Clexane
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Regional budgetary healthcare institution Ivanovskaya clinical hospital named after Kuvaevs, Ivanovo, Russian Federation|State Budgetary Institution of Healthcare Research Institute - Regional Clinical Hospital No. 1 named after Professor S.V. Ochapov Ministry of Health of the Krasnodar Territory, Krasnodar, Russian Federation|Federal State Budgetary Educational Institution of Higher Education Ryazan State Medical University named after academician I.P. Pavlova of the Ministry of Health of the Russian Federation, Ryazan', Russian Federation|State Healthcare Institution Saratov City Clinical Hospital No. 2 named after IN AND. Razumovsky, Saratov, Russian Federation|St. Petersburg State Budgetary Healthcare Institution City Hospital No. 40 of Kurortny District, Sestroretsk, Russian Federation|State budgetary institution of health care of the Yaroslavl region Yaroslavl Regional Clinical Hospital of War Veterans - International Center for the Problems of the Elderly Healthy Longevity, Yaroslavl, Russian Federation
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 399
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - The frequency of DVT|The frequency of PE|The frequency of ischemic stroke|The frequency of AMI|The frequency of arterial thrombotic complication|The proportion of patients transferred to the ICU|The all-cause mortality rate|The all-cause mortality rate during the study|The proportion of patients who stayed in the hospital more than 30 days|The number of days the patient spent in the hospital before discharge due to recovery or positive dynamics, including outpatient follow-up before 30 days expire|Recovery rate|Proportion of patients requiring high-flow oxygen therapy or noninvasive ventilation (NIV)|Changes in the hemostasis system parameters|The efficacy of drugs in patients depends on the D-dimer level at screening
NCT05195047 Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 2) Not yet recruiting Not Applicable Mar/01/2022 Mar/01/2023
  • Alternative id - GUANKE-Trial 2
  • Interventions - Dietary Supplement: 1 week placebo(Week 1)|Dietary Supplement: 1 week of probiotics(Week 1)|Dietary Supplement: 1 week placebo(Week 2)|Dietary Supplement: 1 week of probiotics(Week 2)|Dietary Supplement: 1 week placebo(Week 3)|Dietary Supplement: 1 week of probiotics(Week 3)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Beijing Pinggu Hospital, Beijing, China|Peking University Health Science Center Hospital, Beijing, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other
  • Enrollment - 40
  • Age - 18 Years to 59 Years   (Adult)
  • Outcome measures - The serum neutralizing antibody level of SARS-CoV-2.|IgG antibody concentration|T-cell response level|Serum neutralizing antibody positive rate|Serum neutralizing antibody positive conversion rate|Intestinal flora|Blood pressure|Blood glucose|Blood lipid
Export (.csv)